Drug Trial Radar · NCT02035748
Assessment of Patients Treated With JETREA® for Vitreomacular Traction
Last checked: Nov 20, 2026Latest source record: Oct 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
628
Actual
Start
Apr 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.
Conditions
- Vitreomacular Traction
- Vitreomacular Adhesion
Interventions
OcriplasminDrug
0.5 mg/0.2 mL solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Traction (VMT/VMA) at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) EvaluationTime frame: Baseline, Day 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.